Comparison of single vaccination versus revaccination with a modified-live virus vaccine containing bovine herpesvirus-1, bovine viral diarrhea virus (types 1a and 2a), parainfluenza type 3 virus, and bovine respiratory syncytial virus in the prevention of bovine respiratory disease in cattle.
Objective-To compare effects of administration of a modified-live respiratory virus vaccine once with administration of the same vaccine twice on the health and performance of cattle. Design-Randomized, controlled trial. Animals-612 mixed-breed male cattle with unknown health histories. Procedures-Cattle were randomly assigned to 1 of 2 treatment groups (single vaccination treatment group [SVAC group] vs revaccination treatment group [REVAC group]) during the preconditioning phase of production. All cattle were given a modified-live respiratory virus vaccine. Eleven days later, REVAC group cattle received a second injection of the same vaccine. During the finishing phase of production, cattle from each treatment group were either vaccinated a third time with the modified-live respiratory virus vaccine or given no vaccine. Health observations were performed daily. Blood and performance variables were measured throughout the experiment. Results-During preconditioning, no significant differences were observed in performance or antibody production between groups. Morbidity rate from bovine respiratory disease was lower for SVAC group cattle; however, days to first treatment for bovine respiratory disease were not different between groups. No significant differences in body weights, daily gains, or dry-matter intake between groups were observed during the finishing phase. Revaccination treatment group cattle had improved feed efficiency regardless of vaccination protocol in the finishing phase. Conclusions and Clinical Relevance-Vaccination once with a modified-live respiratory virus vaccine was as efficacious as vaccination twice in the prevention of bovine respiratory disease of high-risk cattle, although feed efficiency was improved in REVAC group cattle during the finishing period.
Step
Douglas L
DL
Department of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Krehbiel
Clinton R
CR
Burciaga-Robles
Luis O
LO
Holland
Ben P
BP
Fulton
Robert W
RW
Confer
Anthony W
AW
Bechtol
David T
DT
Brister
David L
DL
Hutcheson
John P
JP
Newcomb
Harold L
HL
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D001908:Diarrhea Viruses, Bovine Viral / Q000276:immunology*; D007242:Herpesvirus 1, Bovine / Q000276:immunology*; D007117:Immunization, Secondary / Q000009:adverse effects / Q000662:veterinary; D008297:Male; D029101:Parainfluenza Virus 3, Bovine / Q000276:immunology*; D018112:Respiratory Syncytial Virus, Bovine / Q000276:immunology*; D012140:Respiratory Tract Diseases / Q000517:prevention & control / Q000662:veterinary; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
D014765:Viral Vaccines